Trials / Completed
CompletedNCT00736333
A Study to Evaluate Safety and Tolerability in Patients With Metastatic Breast Cancer Receiving Treatment With Caelyx (Study P04878)(COMPLETED)
Observational Program of Caelyx in MBC - Prevention and Treatment of PPE and Infusion Reactions
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 167 (actual)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
This is a study to evaluate the safety and tolerability of Caelyx used for the treatment of metastatic breast cancer (MBC), focusing on infusion reaction and palmar-plantar erythrodysesthesia (PPE).
Detailed description
Patients selected by investigator according to clinical routine
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Liposomal Doxorubicin | Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m\^2, given for up to 6 cycles |
Timeline
- Start date
- 2006-11-01
- Primary completion
- 2010-06-01
- Completion
- 2010-06-01
- First posted
- 2008-08-15
- Last updated
- 2014-11-05
- Results posted
- 2011-07-07
Source: ClinicalTrials.gov record NCT00736333. Inclusion in this directory is not an endorsement.